ASMB — Assembly Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $73.52m
- -$56.72m
- $7.16m
- 25
- 36
- 67
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 16 | 79.1 | 6.25 | 0 | 7.16 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 119 | 144 | 139 | 94.1 | 71.8 |
Operating Profit | -103 | -64.8 | -133 | -94.1 | -64.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -98.4 | -62.2 | -132 | -93.1 | -61.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -97.6 | -62.2 | -130 | -93.1 | -61.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -97.6 | -62.2 | -130 | -93.1 | -61.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -97.6 | -62.2 | -130 | -93.1 | -61.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -44.6 | -19.1 | -28.7 | -22.8 | -13.4 |